Valuation: Emcure Pharmaceuticals Limited

Market Cap 343B 3.57B 3.12B 2.89B 2.67B 5.02B 5.11B 34.42B 13.5B 168B 13.42B 13.12B 579B P/E 2026
32.7x
P/E 2027 * 29.8x
Enterprise Value 350B 3.64B 3.18B 2.94B 2.72B 5.12B 5.21B 35.1B 13.77B 171B 13.68B 13.38B 590B EV / Sales 2026
3.33x
EV / Sales 2027 * 3.33x
Free-Float
18.3%
Yield 2026
0.23%
Yield 2027 * 0.21%
1 day+0.94%
1 week-1.81%
Current month-1.41%
1 month+4.26%
3 months+11.02%
6 months+15.25%
Current year+32.66%
1 week 1,785.5
Extreme 1785.5
1,863.4
1 month 1,704.8
Extreme 1704.8
1,944
Current year 1,381
Extreme 1381
1,944
1 year 1,260
Extreme 1260
1,944
3 years 889
Extreme 889
1,944
5 years 889
Extreme 889
1,944
10 years 889
Extreme 889
1,944
Manager TitleAgeSince
Chief Executive Officer 75 15/04/1981
Director of Finance/CFO - 30/09/2003
Compliance Officer - 03/02/2026
Director TitleAgeSince
Director/Board Member 72 22/07/2001
Chairman 69 -
Director/Board Member 75 15/04/1981
Change 5-day change 1-year change 3-year change Capi.($)
+0.94%-1.81%+33.57% - 3.57B
-2.48%-6.72%+44.19%+156.43% 1,028B
-1.52%-5.01%+61.87%+58.79% 611B
-1.30%-3.88%+27.81%+79.97% 432B
-1.12%-3.68%+26.89%+20.58% 323B
-1.73%-3.45%+26.95%+44.09% 277B
-1.95%-13.92%+15.96%+19.76% 257B
-1.45%-2.37%-27.87%-39.87% 217B
-1.44%-3.49%+19.60%+56.20% 192B
-1.04%-4.63%+16.01%+68.47% 161B
Average -1.02%-3.73%+24.50%+51.60% 350.19B
Weighted average by Cap. -0.90%-4.75%+33.11%+76.73%

Financials

2026 2027 *
Net sales 91.56B 953M 833M 770M 711M 1.34B 1.36B 9.18B 3.6B 44.83B 3.58B 3.5B 154B 104B 1.09B 950M 878M 811M 1.53B 1.56B 10.47B 4.11B 51.12B 4.08B 3.99B 176B
Net income 9.81B 102M 89.26M 82.51M 76.23M 144M 146M 984M 386M 4.8B 384M 375M 16.54B 11.5B 120M 105M 96.69M 89.33M 168M 171M 1.15B 452M 5.63B 450M 440M 19.38B
Net Debt 6.75B 70.26M 61.4M 56.76M 52.44M 98.76M 101M 677M 266M 3.3B 264M 258M 11.38B 4.56B 47.52M 41.53M 38.39M 35.47M 66.79M 68M 458M 180M 2.24B 178M 175M 7.7B
Logo Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active Pharmaceutical Ingredient (APIs). It operates across a wide scope of areas, including Gynecology, Cardiovascular, HIV Antivirals, VMN (Vitamins, Minerals & Nutrients), Pain/Analgesics, Nephrology, Oncology, Anti-Infective, Respiratory, CNS. Its brands include Orofer XT and Pause (Gynecological), Proxym (pain), Tenectase (CNS), Vylda (diabetology), Vitanova (VMN). Its API products include S-Amlodipine, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (Tenecteplase), Vintor (Erythropoietin), TENECTASE (Tenecteplase). It has developed two platforms: Mammalian and Microbial.
Employees
6,731
Date Price Change Volume
14/07/26 ₹1,810.10 +0.94% 138,088
13/07/26 ₹1,793.30 -1.16% 87,267
10/07/26 ₹1,814.40 +0.27% 74,788
09/07/26 ₹1,809.50 +0.01% 148,651
08/07/26 ₹1,809.30 -1.86% 130,096
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1,810.10INR
Average target price
1,913.50INR
Spread / Average Target
+5.71%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EMCURE Stock